
NGM Biopharmaceuticals
A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor | €0.0 Valuation: €0.0 30.6x EV/Revenue -0.9x EV/EBITDA | round | |
* | $122m | Growth Equity VC | |
Total Funding | 000k |









USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | 41 % | (5 %) | (16 %) | (11 %) | (29 %) | (92 %) |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (14 %) | 3 % | (48 %) | (119 %) | (155 %) | (300 %) | (3379 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (18 %) | - | (41 %) | (117 %) | (155 %) | (294 %) | (3223 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 103 % | 88 % | 125 % | 188 % | 208 % | 327 % | 2672 % |
Source: Company filings or news article
Related Content
NGM Bio is a biopharmaceutical company dedicated to discovering and developing novel medicines aimed at transforming the lives of patients affected by serious diseases. The company employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to generate proprietary insights. These insights are used to create promising product candidates that can quickly advance into proof-of-concept studies. NGM Bio's research and development engine is highly productive, with all therapeutic candidates in its pipeline originating from its in-house discovery efforts. The company serves patients with unmet medical needs and operates in the biopharmaceutical market. NGM Bio's business model focuses on leveraging its scientific expertise to develop and commercialize new therapies, thereby generating revenue through the successful advancement and eventual market introduction of its drug candidates. Currently, the company has four programs in active clinical development, supported by a strong financial position and a healthy cash runway.
Keywords: biopharmaceutical, drug discovery, protein engineering, disease biology, patient needs, clinical development, research, development, medicines, therapeutic candidates.